Kirsten H Detrick

Life is an adventure. Enjoy the ride.
CEO/Swiss Representative/Tuck Adjunct Professor/Advisor/Mentor

[Kirsten H Detrick @khdetrick]

Ok this is TERRIFIC!!

[Basel Area Life Sciences Supercluster @BaselArea]

Basel-based #biotech company Nouscom has raised 67.5 million euros in a series C #financing 💸 round. The company will use the funds to advance the clinical #development of its portfolio of neoantigen cancer vaccines. 🧬

💡 Read more here:
https://t.co/qYEgzPAxDf

[Kirsten H Detrick @khdetrick]

@jodipicoult Congratulations!

[ENDPOINT HEALTH @endpointhealth]

Announcing our newest precision immunology program! A first-in-class therapy…an innovative AI platform for patient selection. We aim to transform immune-mediated inflammatory disease treatment with novel precision medicine strategies.

Learn more: https://t.co/AiKnLsIVLC

[Kirsten H Detrick @khdetrick]

So this is pretty darn cool...@endpointhealth was selected as a 2022 @ycombinator "Top Company" https://t.co/ldLmCx2enY

[ENDPOINT HEALTH @endpointhealth]

We are delighted to announce that Endpoint Health was selected for the 2022 @ycombinator Top Companies list. Learn more about this honor and about our company: https://t.co/Qi405lQj8K

[ENDPOINT HEALTH @endpointhealth]

Take a listen to @JasonSprings interview with the @Labiotech_eu Beyond Biotech podcast! He talks about our scientific approach, shares exciting company news, and gives an overview of our unique Precision-First platform.

Full episode here! https://t.co/sRNNif8ijX

[ENDPOINT HEALTH @endpointhealth]

Endpoint Health is driving biopharma 2.0, working to bring targeted therapies to patients as quickly as possible, using our unique approach to the challenge. Our goal is to improve the lives of people with immune-mediated illnesses.

Learn more: https://t.co/ICYK731PZB

[ENDPOINT HEALTH @endpointhealth]

Great people are the key to great success. At Endpoint Health, we’re building a talented team of individuals with incredible achievements, both personally and professionally.

Get to know them now! Together, we’re building a new kind of biopharma: https://t.co/NfKDKQdBwZ

[Jason Springs @EPHJason]

As a CEO, I am proud of the incredible team we’ve been building here at @endpointhealth. This group of seasoned industry professionals is succeeding both at and away from their desks – visit our site to find out what makes them unique: https://t.co/BNvay4n9OB

[ENDPOINT HEALTH @endpointhealth]

An article published today in Forbes offers leadership advice from our very own @DiegoARey, member of the @ForbesTechCncl. Diego tells leaders they shouldn’t be hesitant to launch a company, even if they don't have a fully developed idea. @ForbesCouncils https://t.co/xPDHnwW9d8

[ENDPOINT HEALTH @endpointhealth]

#NewHire: Join us in welcoming Penny Toren as our new SVP of Regulatory Affairs! Penny is a seasoned professional who has provided regulatory leadership for the development, approval, and maintenance of several products in various therapeutic areas.

[ENDPOINT HEALTH @endpointhealth]

Our CEO and co-founder @EPHJason joined the “Talking Precision Medicine” podcast to discuss our work in precision immunology, founder lessons and our approach to building the right team. Give it a listen: https://t.co/omwRAFaEu0

[Jason Springs @EPHJason]

I had the privilege to speak with @rafecooks and the "Talking Precision Medicine" podcast about Endpoint Health's work in precision immunology, insights on founding a company and how to build the right team. Check it out!

[ENDPOINT HEALTH @endpointhealth]

Exciting to see our Series A financing highlighted by @Nasdaq in New York! We’re extremely proud of this milestone and grateful to all those supporting us on the mission to improve outcomes for patients.

[ENDPOINT HEALTH @endpointhealth]

At Endpoint Health, we’re patient-first, not molecule-first.

We are uniquely built to develop and commercialize both targeted therapeutics and therapy-guiding tests that offer patients the potential to receive a therapy personalized to their biology and clinical needs.

[Kirsten H Detrick @khdetrick]

Delighted to announce that @endpointhealth has raised $52 million to expand our pipeline, progress our Precision-FirstTM technology into chronic immune-mediated diseases and advance our #antithrombin III asset into Phase II trials. Read more here -> https://t.co/7zqQoWPx6A

[ENDPOINT HEALTH @endpointhealth]

We’re thrilled to announce that we closed $52 million in equity and debt financing in our Series A to expand and progress our precision immunology pipeline. Read more in our press release here: https://t.co/Q047QaV04Q

[Kirsten H Detrick @khdetrick]

Want to join an amazing team? Check out GHIC!

[ENDPOINT HEALTH @endpointhealth]

Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.

Using our unique #PrecisionFirst approach, we’re on a mission to help make this possible. Learn more: https://t.co/rPrQZL50cM

[ENDPOINT HEALTH @endpointhealth]

At Endpoint Health, we’re on a mission to improve the care of immune-mediated diseases through #PrecisionFirst therapeutics.

Join us today in raising awareness for #WorldIBDDay2022 and show your support for those living with this debilitating, chronic disease.

[Jason Springs @EPHJason]

Our company is always looking for new, innovative thinkers. Join our growing team and help us build a new kind of biopharma.

Explore our current openings: https://t.co/ggKwU6j3tY